Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Rigshospitalet, Copenhagen, Denmark

In this page

How to contact the center

Full member

HCP Center

Rigshospitalet is Denmark's international hospital, which offers highly specialized treatment of citizens in Denmark, the Faroe Islands and Greenland. Rigshospitalet was merged with Glostrup Hospital on 1 January 2015 and is thus the country's largest hospital, where the top experts and researchers ensure that the hospital in its treatment, research and education can measure with the best in Europe. Rigshospitalet is organized in eight centers led by a joint management.
Rigshospitalet's historical background goes back to Denmark's first real hospital, "The Royal Frederiks Hospital", which was established to care and treat poor Copenhageners by attachment. The hospital opened in 1757 and was located in Bredgade, where you can find the Kunstindustrimuseet today. In 1910, the hospital became part of the state and moved to its current location on Blegdamsvej. The hospital also changed its name to Rigshospitalet, as it should be available to all citizens of the Kingdom in the future. The modern Rigshospital, with its tall gray buildings, dates from the 1960s and is today part of the Capital Region.

Picture : Ole Morten Nygård

Contact

Rigshospitalet, Copenhagen, Denmark

Inge Lehmanns Vej 7 Entrance 2, 6. floor Section 2061
2100 Copenhagen
Denmark

Team

Dr Steffen HAMANN

Representative

Denmark

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Pr Michael LARSEN

Representative

Denmark

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Pr Steffen HEEGAARD

Denmark

Neuro-Ophthalmology Rare Diseases (WG2)
See more

Line Kessel

Denmark

Genetic Diagnostics (TWG6), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Clinical trials

NCT05566795 - Recruiting, Active

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Interventional
See the trial
voir la fiche
NCT04526951 - Active, Not recruiting

TENecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): A Randomized Placebo-controlled Trial of Early Systemic Tenecteplase Treatment in Patients With Central Retinal Artery Occlusion.

Interventional
See the trial
voir la fiche

NCT01835002 - Completed

This is a single-arm open label interventional safety trial with RP patients, who receive weekly TES for 6 months on 1 eye followed by observation for another 6 months without stimulation. The primary outcome measure is safety, indicated by the frequency and severity of adverse events.

Interventional
See the trial
voir la fiche
NCT04525261 - Completed

Natural history of patients with inherited retinal diseases due to mutations in RPE65 gene

Observational
See the trial
voir la fiche
RET-IRD-04 - Unknown

Efficacy and safety of QLT091001 in subjects with Inherited Retinal Disease (IRD) caused by gene mutations.

Interventional
See the trial
voir la fiche
NCT03584165 - Recruiting, Active

A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.

Interventional
See the trial
voir la fiche
NCT02771379 - Completed

A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON).

Observational
See the trial
voir la fiche
NCT02575430 - Completed

Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT.

Observational
See the trial
voir la fiche
NCT01954953 - Unknown

Clinical and Genetic Examination of Usher Syndrome Patients’ Cohort in Europe.

Observational
See the trial
voir la fiche
NCT05811351 - Recruiting, Active

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Interventional
See the trial
voir la fiche
NCT05736237 - Recruiting, Active

Identification and Verification of Candidate Genes Responsible for Optic Disc Drusen

Observational
See the trial
voir la fiche
NCT05305079 - Recruiting, Active

Non-Arteritic Anterior Ischemic Optic Neuropathy Risk Factors: New Perspectives

Observational
See the trial
voir la fiche
NCT05248906 - Completed

A Head-to-head Comparison of Ultrasound Versus Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis

Observational
See the trial
voir la fiche